Emerging Technologies I|It can be argued that the pharmaceutical industry is changing at its fastest rate in decades, driven in part by the requirement to manufacture new process modalities, as well as the need to deliver new facilities in a quicker and more cost effective manner. Speed to market and accelerating first-in-human has never been as important. Companies are having to respond to challenges such as increased development complexity, demand volatility, and CoG challenges as a result of increasing competition, pricing pressures and profitability. Furthermore, growing demand for more flexible and sustainable facilities, together with the advancement of new processing and Pharma 4.0 technologies, such as digitization and robotics, requires that Site Master Planning needs to advance accordingly. This session will hear about how two major pharma companies have responded to the above challenging industrial landscape. Merck KGaA will explain how they have introduced a fully continuous bioprocessing platform into a new dedicated bioprocessing centre that facilitates end-to-end convergence of Discovery, CMC Innovation, Development, and Clinical and Commercial supply. Additionally, Bayer will explain how they have adopted a Site Master Planning of the Future approach to accommodate new process modalities, delivery methods, and Pharma 4.0 technologies.